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Abstract
Objective: To calculate the persistence, over a period of eight years, the 
retention rate of first and second-line of treatment with biological agents 
in patients with rheumatoid arthritis, spondyloarthritis and psoriatic arthritis 
and to compare retention rates of the various drugs for each pathology.
Method: Retrospective observational study that included patients affect-
ed by rheumatoid arthritis, spondyloarthritis and psoriatic arthritis, who 
started treatment with biological agents between January 2009 and De-
cember 2012 and followed until December 2016. 
Results: 132, 87 and 33 patients were included in rheumatoid arthritis, 
spondyloarthritis and psoriatic arthritis, respectively. The median retention 
duration of all biological agents for the first and second-line, was 30.9 
months and 14.0 months, respectively for rheumatoid arthritis; 63.06 months 
and 25.6 months, respectively in spondyloarthritis. Psoriatic arthritis  did not 
reach the median (> 70 months in first-line) (first line p = 0.002). Individual 
drug survival in first line: the median retention duration of tocilizumab was 
58.3 months, followed by etanercept (p = 0.79) in rheumatoid arthritis. For 
spondyloarthritis, golimumab and etanercept had greater retention than the 
other drugs (they did not reach the median): adalimumab was 63.0 months 
and for infliximab was 50.1 months. In psoriatic arthritis, golimumab, inflix-
imab and etanercept not reach the median and they had greater retention 
than adalimumab (59.4 months). Individual drug survival in second line: to-
Resumen
Objetivo: Calcular y analizar la persistencia global y por medicamento, 
en primera y segunda línea de tratamiento, en pacientes con artritis reuma-
toide, espondiloartritis axial radiográfica y no radiográfica y artritis psoriási-
ca durante un periodo de ocho años. 
Método: Estudio retrospectivo observacional de persistencia en pacien-
tes que iniciaron su terapia con medicamentos biológicos entre enero de 
2009 y diciembre de 2012 en seguimiento hasta diciembre de 2016.
Resultados: Se analizaron 132, 87 y 33 pacientes con artritis reumatoi-
de, espondiloartritis y artritis psoriásica, respectivamente. La persistencia 
mediana global para los biológicos en primera y segunda línea fueron: 
30,9 meses y 14 meses, respectivamente, en artritis reumatoide; 63,06 
meses y 25,6 meses en espondiloartritis. No se alcanzó la persistencia 
mediana en los ocho años de seguimiento en artritis psoriásica (> 70 
meses) (p = 0,002 para la función de supervivencia entre patologías en 
primera línea). Persistencia mediana alcanzada en primera línea por me-
dicamento: tocilizumab (58,3 meses), seguido de etanercept (44 meses) 
en artritis reumatoide (p = 0,79); en espondiloartritis golimumab y etaner-
cept fueron los más persistentes (no alcanzaron la mediana), seguidos de 
adalimumab (44 meses) e infliximab (50,1 meses). En artritis psoriásica, 
golimumab seguido de infliximab y etanercept fueron los más persistentes 
(no alcanzaron la mediana), y adalimumab (59,4 meses). Persistencia 
mediana alcanzada en segunda línea por medicamento: tocilizumab 
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Introduction
The treatment of rheumatoid arthritis (RA) and spondyloarthritis has im-
proved dramatically with management by biologic agents (tumor necrosis 
factor inhibitors (TNFis), such as infliximab (Ifx), adalimumab (Ada), etan-
ercept (Eta), golimumab (Goli), and certolizumab pegol (Certo), and other 
drugs such as tocilizumab (Toci), rituximab (Ritu), and abatacept (Abat). 
Some of these drugs have been approved for RA, and/or spondyloarthritis 
by the European Medicines Agency and the US Food and Drug Admin-
istration1. Spondyloarthritis is a group of several related but phenotypical-
ly distinct disorders that includes arthritis related to inflammatory bowel 
disease, psoriatic arthritis, ankylosing spondylitis (the prototypic and best 
studied subtype), and others, but the pathologies with major clinical pheno-
types are axial spondyloarthritis (SpA) (radiographic SpA called ankylosing 
spondylitis, and nonradiographic SpA)2 and psoriatic arthritis (PsA)1. De-
spite relevant evidence supporting short-term TNFi efficacy and safety from 
randomized controlled trials3-5, data on their long-term effects are limited.
Persistence with treatment is important for effective disease management, 
especially in chronic diseases that can become more severe over time, such 
as autoimmune and inflammatory conditions. Treatment persistence is de-
fined as the time period from initiation to discontinuation of therapy, and is 
measured by continuation rate, retention rate, and drug survival. Medication 
persistence refers to the act of continuing the treatment for the prescribed 
duration6. Drug retention has been found to be a reliable indicator of overall 
treatment effectiveness in observational studies, given that it is mainly deter-
mined by both drug efficacy and safety profiles7-12.
We performed a retrospective study to calculate the persistence of bio-
logical agents in daily clinical practice in our hospital. The aims of this study 
were to determine, over a period of eight years, the retention rate of first-line 
and second-line, of treatment with biological agents in patients with RA, 
SpA and PsA. The secondary objectives were to compare the retention rates 
of the various drugs for each pathology and to analyze the causes and rates 
of discontinuation of these treatments.
Methods
A retrospective observational study was performed in a hospital in Ma-
drid. The study was approved by the Clinical Research Ethics Committee of 
La Paz University Hospital. The study included patients affected by RA, SpA, 
and PsA who started treatment with biological agents between January 
2009 and December 2012. Biological therapies were dispensed at the 
Pharmacy Department in the hospital. Patients were followed until Decem-
ber 2016 and we determined the eight-year retention rate of the first-line 
and second- line biological drugs. However, due to the small number of pa-
tients taking second-line drugs for PsA, the retention rate for these drugs was 
not calculated. Drug survival was calculated in months (1 month = 30 days). 
Drug survival sub-analyses were conducted by stratifying the study popula-
tion according to the diagnosis (RA, SpA, and PsA). We analyzed the type 
of prescribed biological drugs for three pathologies and the retention rate 
for each drug as well as for all drugs together.
Data were recorded in our software program (FarmaTools 2.5 Dominion) 
for drugs prescribed and dispensed to outpatients. Demographic and clini-
cal data were obtained from the La Paz Database for Biological Therapies 
for Rheumatology, which was created by the Rheumatology Unit of the 
hospital.
In addition, we calculated the number and rates of patients who dis-
continued their first treatment, and the reasons for treatment discontinuation 
were analyzed.
Discontinuations were considered to have occurred when no consecu-
tive reintroduction of treatment was reported or on the date when treatment 
was switched to another biological agent. Observations were recorded at 
the last registered visit to the pharmacy service, where biological agents 
were dispensed for the final time. The reasons for discontinuation were as-
signed to five categories: primary inefficacy (lack of response), secondary 
inefficacy (loss of response or failure), adverse events, remission, and other 
(including loss to follow-up, final treatment for other pathologies, and final 
treatment for other causes).
Statistical analysis
The clinical results are expressed as mean and standard deviation. All 
test were performed using IBM SPSS version 19. Differences in patients´ 
characteristics were examined using the chi-squared test for categorical 
variables and t-test for continuous variables. For statistical significance, 
p-values < 0.05 were considered significant. Persistence was expressed 
in months, and it was exported to an Excel table for statistical analysis 
using SAS 9.3 (SAS Institute Inc., Cary, NC, USA). The retention rate was 
estimated using the Kaplan-Meier method. The median time (in months) 
of retention and the cumulative (patients-year) treatment exposure were 
calculated. These analyses were done on all biological drugs together 
and on each drug individually. The resulting curves were compared with 
the log-rank test.
Results
Our study included 132 patients with RA, 87 patients with SpA (58.6% 
with ankylosing spondylitis), and 33 patients with PsA who started their first 
biological agent between 2009 and 2012. The percentages of patients at 
the end of the study in December 2016 were 43.1%, 64.3%, and 72.7% 
in the RA, SpA, and PsA groups, respectively. Patients who discontinued 
the treatment were 75, 31, and 9 patients in RA, SpA, and PsA groups, re-
spectively. There were no losses due to death or transfer to another hospital. 
The demographic and clinical characteristics as DAS28 (Disease activity 
Score for Rheumatoid Arthritis), SDAI (Simple Disease Activity Index), BAS-
DAI (Bath Ankylonsing Spondylitis Activity Index), ASDAS (Ankylosing Spon-
dylitis Disease Activity Score), CRP (C-reactive protein) and ESR (Erythrocite 
Sedimentation Rate) of the patients at beginning and at the end of the study 
are shown in Table 1. At baseline, the patients’ disease activity parameters 
were considered to be active, and at the end of study, these parameters 
were lower (p < 0.05).
Patients received Ada, Eta, Ifx, and Goli as biological drug therapy 
in the SpA and PsA groups, and moreover Certo, Ritu, Abat, and Toci 
for those in the RA group. Patients started with Ada, Ifx, and Goli more 
frequently in SpA (35.6%, 34.4%, and 16.1%, respectively), with Eta, Ada, 
and Goli in PsA (36.3%, 27.3%, and 21.5%, respectively) and with Eta, 
Ada, and Toci in RA group (31.8%, 12.1%, and 11.3%, respectively).
All-drug survival
In this study, the median retention duration of biological agents for 
the first-line drugs, until the first switch (in months), was longer for PsA 
(> 70 months), and SpA (63.06 months, 95% CI 42.2-83.8) than for RA 
(30.9 months, 95% CI 13.1-48.3). Survival functions in months for RA, 
SpA, and PsA in first- and second-line drugs (p=0.002) are shown in 
figure 1.
Survival rates for first-line drugs at the fifth and eighth years were 35.8%, 
and 22.7% for RA, respectively; 51.0%, and 37.3% for SpA, respectively; 
and 61.9%, and 56.3% for PsA, respectively (Figure 2). 
Individual drug survival
1. Rheumatoid arthritis:
• First-line biological agents:
Significant differences emerged in the survival distribution for each 
drug (p = 0.003). The median retention duration of Toci was 58.3 
months (95% CI 32.4-84.2), followed by Eta at 44.0 months (95% CI 
11.8-76.1, p = 0.79). Eta had more retention than other TNFi drugs: 
cilizumab was the most persistent drug (median 22.1 months) in rheumatoid 
arthritis, and golimumab for spondyloarthritis and psoriatic arthritis.
Conclusions: Tocilizumab and etanercept in rheumatoid arthritis, and 
golimumab in spondyloarthritis and psoriatic arthritis also, were the most 
persistent drugs in first-line and second-line treatment.
(22,1 meses) en artritis reumatoide. Golimumab fue el más persistente en 
espondiloartritis y artritis psoriásica (sin alcanzar la mediana).
Conclusiones: Tocilizumab y etanercept fueron los medicamentos más 
persistentes en artritis reumatoide, y golimumab en espondiloartritis y artri-
tis psoriásica en primera y segunda línea de tratamiento.
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34.9 months for Certo (p = 0.98), 16.6 for Ada (p = 0.021), and 7.7 
for Ifx (p = 0.002). A pairwise comparison analysis of Toci versus 
other biological drugs revealed a statistically significant median 
retention with respect to Ada and Ritu (p = 0.015, and p = 0.009, 
respectively). 
• Second-line biological agents:
No differences were found for second-line treatment in survival drugs 
(p = 0.096). 
Toci was the most persistent biological drug, with a median of 22.1 
months (95% CI 10.1-33.9), followed by Abat and Ada with 11.0 
(95% CI 0.0-25.4), and 8.0 (95% CI 5.8-10.4), respectively.
2. Spondyloarthropathies:
• First-line biological agents:
In SpA, the three-year drug survival rate in our study was (64.4%) 
and the eight-year drug survival rate was (37.3%). No significant 
differences emerged in the survival distribution for all of the drugs for 
SpA (p = 0.586). Goli and Eta had greater retention than the other 
TNFi drugs, but they did not reach the median. The median retention 
duration for Ada was 63.0 months (95% CI 34.3-91.7), and for Ifx it 
was 50.1 months (95% CI 23.8-76.4).
• Second-line biological agents:
Goli, as it happened in the first-line, was the most persistent biologi-
cal drug. It did not reach the median reaching a drug survival rate of 
71.1% at the third year.
The median retention of Ifx was 19.7 months, followed by Ada and 
Eta with 10.1 (95% CI 0.39-19.8) and 5.7 (95% CI 0.0-17.7), respec-
tively. No significant differences were found (p=0.129). Our study 
showed a survival rate of Ifx (50%) and Ada (33.3%) at the second 
year, and Eta (16.7%) at the first year. 
3. Psoriatic arthritis: 
• First-line biological agents:
The retention duration of the first, second (median), and third percen-
tile until the first switch to other drugs, all together, was 78.1, 59.4, 
and 42.3 months, respectively. 
Goli, Ifx, and Eta did not reach the median, and they had greater 
retention than Ada (median 59.4 months [95% CI 11.2-77.6]). 
The three-year survival rate for all-drugs was 69.7%, and the eight-
year survival rate was 56.3%.
The cumulative proportional drug survival at 7 years was 85.7%, 
60.0%, 52.5%, and 44.4% for Goli, Ifx, Eta. and Ada, respectively.
Table 1. Demographic and clinical parameters of the patient at baseline and at the end of study
Rheumatoid arthritis At base line End of study p*
Patients (n) (%) 132 (100%) 57 (43.18%)
Ages (years) 51.67 (15.66)
Gender (women) 100 (75.7%) 49 (86%) p < 0.05**
DAS 28 4.78 (1.31) 3.39 (1.28) p < 0.001
SDAI 26.97 (13.51) 11.58 (10.39) p < 0.001
CRP 8.02 SD 9.55 5.05 SD 6.10 p < 0.01
ESR 23 SD15 18.83 SD13.77 p < 0.05
Spondiloarthritis At base line End of study p*
Patients (n) (%) 87 (100%) 56 (64.36%)
Ages (years) 40.95 (11.66)
Gender (men) 54 (62.06%) 36 (64.2%) p = 0.34**
HLA B-27 (+) 58.6%
DAS 28 3.29 (1.15) 2.48 (1.02) p < 0.001
BASDAI 6.30 (1.77) 3.62 (2.35) p < 0.001
ASDAS 3.58 (0.89) 2.11 (0.98) p < 0.001
CPR 12.92 (19.72) 5.63 (9.34) p < 0.01
ESR 18 (16) 12 (10) p < 0.01
Psoriasic arthritis At base line End of study p*
Patients (n) (%) 33 (100%) 24 (72.72%)
Ages (years) 48.82 (11.20)
Gender (men) 22 (66.6%) 17 (70.8%) p=0.036**
DAS 28 4.63 (1.15) 2.55 (0.86) p<0.001
BASDAI 25.99 (9.67) 7.05 (5.06) p<0.001
SDAI 5.31 (2.38) 3.26 (1.79) p<0.01
CRP 15.38 (19.20) 4.70 (8.33) p<0.01
ESR 30 (23) 14 (9) p<0.01
Data are expresed as mean (SD) for continuous variables and frequencies (percentage) for categorical variables.
ASDAS: Ankylosing Spondylitis Disease Activity Score; BASDAI: Bath Ankylonsing Spondylitis Activity Index; CPR: C-reactive protein; DAS 28: Disease activity Score for 
Rheumatoid Arthritis; ESR: Erythrocite Sedimentation Rate; HLA B-27: Human leukocyte antigen B27; SDAI: Simple Disease Activity Index.
Statistical signification P < 0.05; *T test; **Chi-square test.
Inactive disease: ASDAS < 1.3, DAS28 < 2.6, SDAI ≤ 3.3, and BASDAI ≤ 2.
Moderate diasease: ASDAS >1.3 and < 2.1, DAS28 ≥ 3.2 and ≤ 5.1.
Low activity: DAS28 ≥ 2.6 and < 3.2, SDAI > 3.3 and < 11
Clinical control: BASDAI < 4 and Δ ASDAS ≥ 1.1
(Reumatol Clin. 2015;11:279-94; Reumatol Clin. 2011;7:113-23)
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Figure 1. Survival functions in months for rheumathoid arthritis, spondyloarthritis and psoriatic arthritis. PsA: psoriatic arthritis; RA: rheumathoid arthritis; SpA: spond-
yloarthritis.
Figure 2. Survival rates of 
patient in various patholo-
gies per years.
First-line Second-line
Fig. 1 . Survival functions in months for Rheumatoid Arthritis, Spondyloarthritis and Psoriatic Arthritis
 first-line second-line
RA: Rheumathoid Arthritis; SpA: Spondyloarthritis; PsA:  Psoriatic Arthritis
Fig. 1 . Survival functi ns in months for Rheumatoid Ar hritis, Sp ndyloarthritis and Psoriatic Arthritis
 first-line second-line
RA: Rheumathoid Arthritis; SpA: Spondyloarthritis; PsA:  Psoriatic Arthritis
F g. 1 . Survival functions in months for Rheumatoid Arthritis, Spondyloarthritis and Psoriatic Arthritis
 first-line second-line
RA: Rheumathoid Arthritis; SpA: Spondyloarthritis; PsA:  Psoriatic Arthritis
 . urvival functions in months for Rheumatoid Arthritis, Spondyloarthritis and Psoriatic Arthritis
li e seco d-line
R : Rheu athoid Arthritis; SpA: Spondyloarthritis; PsA:  Psoriatic Arthritis
Fig. 1 . Survival functio s in month  for Rh umatoid Arthrit s, Spondylo rthritis and Ps ri i i
 first-line second-line
RA: Rheumathoid Arthritis; SpA: Spondyloarthritis; PsA:  Psoriatic Arthritis
A B
C
005_11080_Persistencia de medicamentos biológicos_ING.indd   27 8/1/19   7:48
28
Farmacia Hospi ta lar ia 2019l 
Vol. 43 l Nº 1 l 24 - 30 l María Ángeles González-Fernández et al.
Table 2. Causes and percentages of discontinuations
RA SpA PsA
TOTAL PATIENTS FOLLOW-UP  132 87 33
Lost to follow-up 5 (3.78%) 5 (5.74%) 0
Inefficacy primary 8 (6.01%) 3 (3.44%) 0
Inefficacy secondary 10 (7.57%) 4 (4.59%) 2 (6.0%)
Adverse events 11 (8.33%) 4 (4.59%) 2 (6.0%)
Interstitial lung disease 1 2 -
Cutaneous lesions 1 - -
Infections 2 1 2
No data 7 - -
Paresthesias - 1 -
Remission 10 (7.57%) 5 (5.74%) 4 (12.12%)
Other pathologies 5 (3.78%) 0 1 (3.03%)
Neoplasias  2 - 1
Heart pathology 1 - -
No data 2 - -
Others causes 9 (6.81%) 3 (3.44%) 0
Surgery 1 - -
Traslate other hospital 1 - -
No data 7 3 -
DISCONTINUATION TREATMENTS  58 (43.93%) 24 (27.58%) 9 (27.27%)
RA: rheumathoid arthritis; SpA: spondyloarthritis; PsA: psoriatic arthritis.
Reasons for discontinuation
A total of 58/132 (43.9%), 24/87 (27.58%), and 9/33 (27.3%) patients 
stopped the first-line biological therapy in RA, SpA, and PsA, respectively. 
There were no losses due to death or transfer to another hospital. Disconti-
nuation was due to primary inefficacy in 13.79% and 12.5% of patients 
with RA and SpA, respectively. Discontinuation was due to secondary in-
efficacy in 17.2%, 16.6%, and 8.3% for patients with RA, SpA, and PsA, 
respectively, and due to adverse events in 18.96%, 16.6%, and 8.3% in pa-
tients with RA, SpA, and PsA, respectively. Other causes and  percen tages 
of discontinuations are reported in Table 2.
Discussion
In this study, the median retention duration of biological agents for first-
line treatment, until the first switch (in months), was longer for PsA (> 70) 
and SpA (63.06) than for RA (30.9), respectively. The survival rate in the 
fifth and eighth years were 35.8% and 22.7% for RA, respectively; 47.7% 
and 37.3%, for SpA, respectively; and 61.9% and 56.3% PsA, respectively. 
There were greater differences between the results obtained for the two first 
pathologies with respect to RA.
Our results on drug survival of TNFi treatments in SpA compared with 
RA were similar to those published by other authors13. In our study, we found 
differences in the discontinuation rate of biological agents when comparing 
first- versus second-line therapy with biological agents. The duration of TNFi 
treatment as second-line therapy was shorter than in the first-line (30.9 versus 
14.0 months in RA and 63.07 versus 25.6 months in SpA). In line with these 
results, other studies13-15 also suggest that a second TNFi (involving only TN-
Fis, such as Ada, Eta, and Ifx, but no other biological drugs) are effective, 
but generally for less time.
In our study, the duration of efficacy of TNFis in RA was 30.9 months 
in first-line. Similarly, Frazier et al. publish that in RA the median retention 
duration of TNFi are 36 months15. We observed a longer median retention 
duration for Toci and Eta (58.3 and 44.0 months, respectively) compared 
with other biological agents. 
Recent studies report a lower discontinuation rate for Eta, mainly be-
cause it was better tolerated than Ada and Ifx16. We observed a similar 
retention duration for Eta when comparing our results with the Frazier et al. 
report (44 months versus 45 months). However, drug survival times for Ada 
and Ifx in our study were much shorter (16.6 and 7.7 months versus 31 and 
23 months, respectively).
It should be noted that all studies only compare these three TNFi drugs. 
To our knowledge, no other comparisons of all biologicals available for 
rheumatic diseases such as those in our study have been published15-19. 
For second-line drugs, our study showed that Toci (median retention 22.1 
months) was the most persistent, followed by Abat, Ada, and other TNFi 
treatments. Some observational studies compare the efficacy and retention 
of rituximab, Abat, and Certo as a second TNFi; however, they do not ex-
ceed one year of follow-up20-22. A systematic review conclude that switching 
to Abat, Ritu, and Toci are more effective than cycling TNFi in patients with 
an inadequate response to TNFis23.
In SpA, the three-year survival rate in our study (64.4%) was consistent 
with data reported in the Italian cohort MonitorNet (69%)24, and was lower 
than data reported by the Spanish Society of Rheumatology (76%)25 or 
reported by Favalli et al. (72%)7.
The eight-year survival rate for SpA in our study (37.3%) was lower than 
that of Favalli’s study (57.2%). This difference is probably due to the smaller 
number of patients in our study (88 patients) compared with theirs (316 pa-
tients).
If we analyze the order in the first-line drug survival after 5 years, Goli 
and Eta (64.3% and 58.3%, respectively) were more persistent than Ada 
and Ifx (51.6% and 42.7%, respectively). The persistence concurs with data 
reported by Favalli et al., who find an estimated proportion of patients 
maintaining Eta, Ada, and Ifx of 79.9%, 76.2%, and 64%%, respectively, 
after 5 years. However Goli is not included in their study period, as only 3 
TNFis were available in Italy7. The survival order in Favalli’s study changed 
after eight years (76.2%, 69.2%, and 50.7% for Ada, Eta, and Ifx, respec-
tively). Our results were different for Goli, Eta, Ifx, and Ada (64.3%, 58.3%, 
34.1%, and 29.5%, respectively). Favalli et al. explain their results for Ada 
persistence by considering the frequent coexistence in SpA of extra-articular 
manifestations such as uveitis and inflammatory bowel disease, in which 
TNFis have been proven to be more effective than Eta, thus affecting drug 
survival7. 
For second-line drugs for SpA, our study showed that Goli at the third 
year was again the most persistent (71.1%), followed by Ifx (50%), and 
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Ada (33.3%) at the second year, and Eta (16.7%) at the first year. To our 
knowledge, no other studies have been published in which the rate survival 
in the second-line drugs for SpA has been calculated, such as those of our 
study. Favalli et al. have been published a study in which second-line Goli 
shows an overall better 2-year drug survival compared with Ada and Eta26.
For first-line drugs for PsA, the three-year survival rate in our study (69.7%) 
was lower than that reported by the Spanish Society of Rheumatology 
(73%)25 and higher than that reported by the Italian cohort MonitorNet24 
and Favalli7 (both 64%) and the British Society of Rheumatology Biologic 
Register (59%)27.
The eight-year survival rate in our study (56.3%) was longer than Favalli’s 
study (51.9%), although our results might have less consistency because we 
started with a very small sample (33 patients) compared with that of Favalli 
(298 patients).
In our study, the cumulative drug survival proportion of patients at eight 
years was 85.7%, 60.0%, 52.5%, and 44.4% for Goli, Ifx, Eta, and Ada, 
respectively. These results do not concur with data reported by Favalli et 
al. in which the drug survival rate after eight years is 65.8%, 51.8%, and 
44.9% for Eta, Ada, and Ifx, respectively. Ifx survival in patients with PsA in 
our study was longer and Ada shorter. Goli was the drug with the longest 
survival in both PsA and SpA in our study.
The causes of discontinuation were mostly adverse events (mainly infections) 
followed by secondary inefficacy and primary inefficacy, in concordance with 
a previous study performed in our hospital that enroll 531 patients with rheu-
matic diseases (53.1% with RA and 46.9% with SpA and PsA), which shows 
that immunogenicity and infections are the most frequent causes of disconti-
nuation28. However, the total percentage of discontinuations (11.7%) is lower 
than in our study, because the population of our study was smaller, probably.
Favalli et al. report a discontinuation higher than our study (42.08% and 
44.63% for SpA and PsA, respectively)7. Discontinuations due to secondary 
inefficacy are higher in Favalli s´ study (32.33% in SpA and 40.60% in PsA). 
Adverse events (3.00% in SpA and 9.02% in PsA) are lower and similar, 
respectively. Primary inefficacy is lower in SpA (5.26%) and higher in PsA 
(9.77%).
Limitations
This study has some limitations, such as the fact that there are no data on 
the time from diagnosis to the first biological treatment, nor data on the pre-
sence or absence of concomitant synthetic disease-modifying anti-rheumatic 
drugs. Concomitant methotrexate improves drug survival in patients with 
PsA29 and undifferentiated spondyloarthritis30 and significantly increases the 
survival of both Ada and Eta in RA19. Another limitation is the small number 
of patients, especially in PsA, which could affect the consistency of the 
results. Another limitation is that in the calculated persistence, we have as-
sumed that patients were adherent to the treatment after withdrawing their 
medication dispensed in the pharmacy service, because this withdrawal 
does not imply that all patients administer it.
The main contribution of our study is the long study period and the in-
clusion of all possible biological drugs for the treatment of these rheumatic 
pathologies. These results add to the results previously published, in which 
only the short-term or related persistence of the anti-TNF drugs Eta, Ada, 
and Ifx were studied. 
In conclusion, although this study has some limitations, we report that 
Toci and Eta for RA, and Goli for SpA, and PsA are associated with high 
long-term persistence and a good profile of safety as first-line treatment. 
When second-line treatment was prescribed, Toci for RA, and Goli for SpA, 
and PsA also had a better retention rate than other biological agents. Dis-
continuation of these drugs in RA was higher than in SpA and PsA (both 
similar), and the most frequent reason was adverse events in RA and remis-
sion in SpA and PsA.
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Contribution to the scientific literature 
Our study on the persistence of medications for rheumatic conditions 
contributes with two important aspects to scientific literature: firstly, it is 
a persistence study, and therefore with health outcomes of biologics at 
long term, specifically with an eight-year follow-up, both for rheumatoid 
arthritis and axial spondyloarthritis, radiological (ankylosating spondyli-
tis) and non-radiological, as well as for psoriatic arthritis. The clinical 
parameters of each condition are inherent to these health outcomes, di-
rectly associated with the clinical situation of the patient, as well as drug 
safety and its good tolerability by patients. Secondly, all medications 
indicated for these three conditions are included, up to and including 
the year 2016, unlike most published studies which only include persis-
tence studies for anti-TNF drugs. 
Awareness of these data could be useful in our setting, as they can 
help to make decisions at the time of prescribing biologics at first line 
based on their persistence over time: considering that all biologic medi-
cations for these conditions are equally effective, prescribing those with 
higher persistence would therefore mean prescribing the more efficient 
options at long term. 
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